| Name | Alectinib hydrochloride |
| Description | Alectinib hydrochloride (RO5424802 Hydrochloride) is a selective, and orally available inhibitor of ALK( IC50 : 1.9 nM) |
| Animal Research | Animal Model:SCID or nude mice bearing NCI-H2228 cells. Dosage:0.2 mg/kg, 0.6 mg/kg, 2 mg/kg, 6 mg/kg, 20 mg/kg. Administration:Oral administration; once daily; for 11 days |
| In vivo | Alectinib hydrochloride(CH5424802), a potent, selective, and orally available ALK inhibitor with a unique chemical scaffold, showing preferential antitumor activity against cancers with gene alterations of ALK, such as nonsmall cell lung cancer (NSCLC) cells expressing EML4-ALK fusion and anaplastic large-cell lymphoma (ALCL) cells expressing NPM-ALK fusion in vitro and in vivo |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 6.25 mg/mL (12.04 mM), Sonication is recommended.
|
| Keywords | RO-5424802 | RO5424802 | RO 5424802 | Inhibitor | inhibit | Cluster of differentiation 246 | CH-5424802 | CH5424802 | CH 5424802 | CD246 | Anaplastic lymphoma kinase (ALK) | Anaplastic lymphoma kinase | ALK tyrosine kinase receptor | ALK | Alectinib hydrochloride | Alectinib Hydrochloride | Alectinib | AF-802 | AF802 | AF 802 |
| Inhibitors Related | Entrectinib | DMH-1 | SB-431542 | ALK-IN-1 | RepSox | EML4-ALK kinase inhibitor 1 | Crizotinib | Vactosertib | Ceritinib | LDN-193189 2HCl | Brigatinib | A 83-01 |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
United States
